Retinal Gene Therapy for Choroideremia

Active Clinical Trials // Clinical Trials // Jul 16 2018


Clinical Trial of Retinal Gene Therapy for Choroideremia

Sponsor: Night Therapeutics

Principal Investigator: Kimberly Stepien, MD

Study Coordinator: Nickie Stangel

Study Objective:

To evaluate the efficacy and sagety of a single subretinal injection of AAV2-REP1 in subjects with choroideremia (CHM)

Study Design:

This is a surgical trial enrolling patients who qualify that are currently in the NIGHT natural history of choroideremia trial. The study consists of 8 visits with a 12 month evaluation period.

Subjects must be currently enrolled in the Natural History Choroideremia observational trial.

For more information, contact Nickie Stangel 608-263-8783